|
, Skin disorder, Maculopapular rashCommon1(1-10%)Dry skin, Urticaria, Acne, Alopecia, Eczema, Petechial Rash, Photosensitivity reaction, Exfoliative dermatitis, Skin discoloration, Dermatitis bullous, SeborrhoeaUncommon2(0.1-1%)Angioneurotic oedemaRarePemphigus, Stevens-Johnsons's syndromeMusculoskeletal and Connective Tissue DisordersVery common(>10%)Myalgia, Bone disorder, ArthropathyCommon1(1-10%)Arthralgia, ArthritisUncommon2(0.1-1%)Pain in extremitiesRenal and Urinary DisordersVery common(10%)Genito-urinary disorder, BUN increasedCommon1(1-10%)Creatinine increased, Renal impairment, Nephropathy, Renal failure, Nephrolithiasis, Acute renal failure, Dysuria, Urinary retentionUncommon2(0.1-1%)Cystitis haemorrhagicReproductive system and breast disorders: Common1(1-10%)Amenorrhoea, Breast mass, Erectile dysfunctionGeneral Disorders and Administration Site ConditionsVery common(>10%)Fever, fatigue, chills, asthenia, painCommon1(1-10%)Chest pain, Death, Face oedema, Peripheral oedema, Flu-like symptoms, Hangover, Back pain, MalaiseUncommon2(0.1-1%)Mucositis, Multiorgan failureRare2(0.01-0.1%)Systemic inflammatory response syndrome, Lower extremity tenderness1Includes all events which occurred in less than 3% of NIPENT-treated patients during the initial phase of the SWOG study:2Based on 1549 patients included in post-marketing studies through Oct 10, 2005.3Reported only in GVHD studies.
Manufacturer
Hospira UK Ltd
Drug Availability
(POM)
Updated
01 June 2009
|
